Celldex Therapeutics (CLDX) Asset Writedowns and Impairment (2017 - 2021)

Celldex Therapeutics' Asset Writedowns and Impairment history runs 5 years deep, the most recent figure standing at $3.5 million for Q3 2021.

• In Q3 2021, Asset Writedowns and Impairment changed N/A year-over-year to $3.5 million; the TTM figure through Sep 2021 stood at $21.5 million (changed N/A YoY), while the FY2021 annual figure was $3.5 million, down 80.56% from the prior year.
• Asset Writedowns and Impairment for Q3 2021 stood at $3.5 million, down from $14.5 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $14.5 million in Q4 2020, with the low at $1.8 million in Q1 2019.
• The 5-year median for Asset Writedowns and Impairment is $6.9 million (2018), against an average of $7.9 million.
• Peak annual rise in Asset Writedowns and Impairment reached 84.75% in 2019, while the deepest fall reached 84.75% in 2019.
• Celldex Therapeutics' Asset Writedowns and Impairment stood at $13.0 million in 2017, then sank by 47.1% to $6.9 million in 2018, then slumped by 73.83% to $1.8 million in 2019, then surged by 705.56% to $14.5 million in 2020, then plunged by 75.86% to $3.5 million in 2021.
• Business Quant data shows CLDX's Asset Writedowns and Impairment at $3.5 million in Q3 2021, $14.5 million in Q4 2020, and $3.5 million in Q2 2020.